loading page

Allogeneic CD34+ Selected Hematopoietic Stem Cell Boost Following CAR T-cell Therapy in a Patient with Prolonged Cytopenia and Active Infection
  • +6
  • Amanda Lipsitt,
  • Lisa Beattie,
  • Elaine Harstead,
  • Ying Li,
  • Salil Goorha,
  • Gabriela Maron,
  • Stephen Gottschalk,
  • Brandon Triplett,
  • Swati Naik
Amanda Lipsitt
St Jude Children's Research Hospital

Corresponding Author:amanda.lipsitt@stjude.org

Author Profile
Lisa Beattie
St Jude Children's Research Hospital
Author Profile
Elaine Harstead
St Jude Children's Research Hospital
Author Profile
Ying Li
St Jude Children's Research Hospital
Author Profile
Salil Goorha
Baptist Cancer Center
Author Profile
Gabriela Maron
St Jude Children's Research Hospital
Author Profile
Stephen Gottschalk
St Jude Children's Research Hospital
Author Profile
Brandon Triplett
St Jude Children's Research Hospital
Author Profile
Swati Naik
St Jude Children's Research Hospital
Author Profile

Abstract

Hematological toxicity (hematotoxicity) is the most common long-term adverse effect following the use of CD19-chimeric antigen receptor (CD19-CAR) T-cell therapies. However, its management remains unclear. We present the case of a 21-year-old who received CD19-CAR T-cell therapy for relapse following a haploidentical transplant. He developed hematotoxicity and consequently multiple life-threatening infections. We administered a CD34+ hematopoietic stem cell boost (HSCB) from his transplant donor that led to hematopoietic recovery and resolution of his infections without any effect on the activity of CD19-CAR T cells. CD34+ HSCB can be a safe and effective option to treat hematotoxicity following CD19-CAR T-cell therapy.
13 Sep 2022Submitted to Pediatric Blood & Cancer
13 Sep 2022Submission Checks Completed
13 Sep 2022Assigned to Editor
14 Sep 2022Reviewer(s) Assigned
05 Oct 2022Review(s) Completed, Editorial Evaluation Pending
09 Oct 2022Editorial Decision: Revise Minor
09 Nov 2022Submission Checks Completed
09 Nov 2022Assigned to Editor
09 Nov 20221st Revision Received
09 Nov 2022Review(s) Completed, Editorial Evaluation Pending
09 Nov 2022Reviewer(s) Assigned
30 Nov 2022Editorial Decision: Accept